The Australian Government has reached an agreement with Sanofi and Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) to ensure Dupixent® (dupilumab) remains listed on the Pharmaceuticals Benefits Scheme (PBS) for eczema treatment, as it has been since 2021. In July 2024, higher than expected prescription numbers had risked Dupixent® being withdrawn from the PBS. Eczema Support Australia lobbied in support of the continued listing and has welcomed the decision.
Dupixent® will be considered in March 2025 for PBS listing for severe atopic dermatitis and uncontrolled severe asthma.